A9508 I-131 iobenguane | HCPCS Reimbursement | OpenPayer

Summary & Overview

HCPCS Level II A9508: Iodine I-131 iobenguane sulfate, Diagnostic

HCPCS Level II code A9508 identifies a diagnostic radiopharmaceutical: iodine I-131 iobenguane sulfate, billed per 0.5 millicurie for nuclear medicine imaging. This agent is used to localize and image tumors and tissues that concentrate iobenguane, making it clinically important for diagnosing certain neuroendocrine and neuroblastoma-related conditions. Nationally, payment and coverage policies for radiopharmaceuticals affect access to specialized diagnostic imaging and influence facility reimbursement patterns for services requiring licensed handling and imaging infrastructure.

Key payers referenced include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context, typical sites of service, and the billing framework for this HCPCS Level II code. The publication also summarizes benchmark considerations, common modifiers used with radiopharmaceuticals, and policy topics relevant to payers and providers such as coverage criteria, claims processing nuances, and billing units tied to activity (millicurie) reporting.

This overview is intended for billing managers, nuclear medicine departments, and policy analysts seeking a national-level briefing on code A9508, its clinical role, and the payment environment surrounding diagnostic radiopharmaceuticals.

AetnaBlue Cross Blue ShieldCigna HealthUnitedHealthcareMedicareA9508HCPCS Level IIradiopharmaceuticalnuclear medicinediagnostic imagingiodine I-131iobenguaneradiology billingimaging agent

Billing Code Overview

HCPCS Level II code A9508 represents Iodine I-131 iobenguane sulfate, diagnostic, per 0.5 millicurie. This code denotes a radiopharmaceutical diagnostic agent used for imaging and localization of certain neuroendocrine tumors and related conditions that take up iobenguane.

Service Type: Diagnostic radiopharmaceutical administration (nuclear medicine diagnostic agent)

Typical Site of Service: Hospital outpatient department, hospital nuclear medicine department, freestanding imaging centers with nuclear medicine capability, or specialty clinics providing diagnostic nuclear medicine services

Clinical & Coding Specifications

Clinical Context

A typical patient is an adult or pediatric patient referred to nuclear medicine for diagnostic localization and functional assessment of neuroendocrine tumors, primarily suspected or known pheochromocytoma or paraganglioma. The ordering clinician (endocrinologist, oncologist, or surgeon) requests an imaging study using I-131 iobenguane (MIBG) to detect catecholamine-producing tumors when biochemical testing (elevated plasma or urine metanephrines/normetanephrines) and cross-sectional imaging (CT or MRI) are inconclusive or when whole-body functional imaging is required for staging.

Clinical workflow:

Patient preparation includes medication review and withdrawal of interfering drugs (e.g., labetalol, tricyclic antidepressants) per nuclear medicine protocol, thyroid blockade (potassium iodide or Lugol's solution) to protect the thyroid prior to administration, and pregnancy test for women of childbearing potential.
On the day of service, radiopharmacy dispenses I-131 iobenguane sulfate in the ordered activity, billed per 0.5 millicurie unit using A9508.
Administration is performed by nuclear medicine nursing or a qualified technologist under physician supervision; vital signs and radiation safety precautions are observed. Imaging is typically performed at delayed time points (24–72 hours or later) with planar and SPECT/CT as indicated.
Post-procedure, radiation precautions and discharge instructions are provided. Results are interpreted by a nuclear medicine physician, with findings communicated to the referring provider for management decisions including surgery, systemic therapy, or additional imaging.

Coding Specifications

HCPCS Level II A9524: Iodine I-131 Iodinated Serum Albumin, Diagnostic

HCPCS-A9517-IODINE-I131-SODIUM-IODIDE-THERAPEUTIC-CAPSULE-PER-MILLICURIE

HCPCS A9517: Iodine I-131 Sodium Iodide Capsules, Therapeutic

HCPCS-A9539-TECHNETIUM-TC-99M-PENTETATE-DIAGNOSTIC

HCPCS A9539: Technetium Tc-99m Pentetate, Diagnostic Study Dose

HCPCS-A9552-FLUORODEOXYGLUCOSE-FDG-PER-STUDY-DOSE-UP-TO-45-MILLICURIES

HCPCS A9552: Fluorodeoxyglucose F-18 (FDG) per Study Dose, up to 45 mCi

HCPCS-A9612-FLUORESCEIN-INJECTION-1MG-DIAGNOSTIC

HCPCS A9612: Injection, Fluorescein, 1 mg

HCPCS-A9532-IODINE-I-125-SERUM-ALBUMIN-DIAGNOSTIC

HCPCS A9532: Iodine I-125 Serum Albumin, Diagnostic, per 5 microcuries

HCPCS-A9900-DME-SUPPLY-ACCESSORY-SERVICE-COMPONENT

HCPCS A9900: Miscellaneous DME Supply, Accessory, or Service Component

HCPCS-A9608-FLOTUFOLASTAT-F18-DIAGNOSTIC-1-MILLICURIE

HCPCS A9608: Flotufolastat F 18 Diagnostic, 1 Millicurie

HCPCS-A9570-INDIUM-111-LABELED-AUTOLOGOUS-WBC-DIAGNOSTIC

HCPCS A9570: Indium-111 Labeled Autologous White Blood Cell Study

HCPCS-A9282-WIG-SUPPLY

HCPCS Level II A9282: Wig, Any Type, Each

Showing 1–10 of 138

Modifier	Description	When to Use
`00`	Standard reporting modifier (no special modifier)	Use when no additional modifier applies and service is billed routinely.
`22`	Increased procedural services	Use when work or resources substantially exceed usual expectations for preparation, administration, or imaging related to `A9508`.
`23`	Unusual anesthesia	Use when general anesthesia or exceptional anesthesia is required for administration or imaging due to patient condition.
`52`	Reduced services	Use when a partial dose or abbreviated study is provided relative to the ordered service.
`53`	Discontinued procedure	Use when administration or imaging is started but halted for patient safety reasons.
`62`	Two surgeons	Use when two physicians of different specialties are required for safe administration or concomitant interventional procedure.
`80`	Assistant surgeon	Use when an assistant surgeon provides substantial help during a procedural component associated with administration or biopsy performed under the same encounter.
`82`	Assistant surgeon (when qualified resident unavailable)	Use when an assistant surgeon is used and `80` is not appropriate.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services for assistant-at-surgery	Use when an APP serves as an assistant in a surgical procedure related to findings from the MIBG study.
`QX`	Modifier indicating assistant-at-surgery services furnished by a physician’s assistant	Use per payer policy when a PA documents assistant-at-surgery work related to subsequent procedures.

Taxonomy Code	Specialty	Notes
208K00000X	Nuclear Medicine Physician	Interprets study, oversees radiopharmacy and administration.
207RC0000X	Radiology - Diagnostic Radiology	May perform SPECT/CT correlation and comprehensive imaging interpretation.
2085P0800X	Endocrinology	Refers patients for biochemical workup and interpretation of results in tumor management.
207L00000X	General Surgery	Performs operative management guided by imaging findings.
363LP0808X	Nuclear Medicine Technologist	Performs radiopharmaceutical administration, imaging acquisition, and radiation safety.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`C74.01`	Malignant neoplasm of right adrenal gland	Primary adrenal pheochromocytoma appears in adrenal tissue; `I-131 iobenguane` localizes catecholamine-producing lesions.
`C74.02`	Malignant neoplasm of left adrenal gland	See above for left-sided adrenal involvement.
`D35.00`	Benign neoplasm of unspecified adrenal gland	Benign adrenal tumors such as sympathetic paragangliomas or benign pheochromocytomas may be evaluated with MIBG imaging.
`G90.9`	Disorder of the autonomic nervous system, unspecified	Dysautonomia with suspected neuroendocrine tumor requiring functional localization.
`C75.4`	Malignant neoplasm of chromaffin tissue of adrenal gland and sympathetic nervous system	Includes extra-adrenal paragangliomas and catecholamine-secreting tumors targeted by `I-131 iobenguane` imaging.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`78800`	Radiopharmaceutical therapy and imaging agent, diagnostic, radiopharmaceutical localization of radiopharmaceutical (eg, I-131 MIBG) planar imaging, single area; initial day	Used for planar imaging acquisition associated with I-131 MIBG diagnostic localization when billed separately from the radiopharmaceutical.
`78803`	Radiopharmaceutical localization of radiopharmaceutical (eg, I-131 MIBG), tomographic (SPECT) including partial or whole body SPECT/CT when performed	Used when SPECT or SPECT/CT is performed for improved anatomic localization after administration of `A9508`.
`99000`	Handling and/or monitoring of radioactive materials	Ancillary service sometimes billed by facilities for handling and monitoring radiopharmaceuticals; may be relevant in facility charge structures related to `A9508` administration.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	May be used if local injection is performed for comparative radiopharmaceutical studies or adjunct procedures in the same encounter.
`36415`	Collection of venous blood by venipuncture	Performed for pre-procedure laboratory testing such as pregnancy test or baseline labs prior to radiopharmaceutical administration.

OpenPayer